[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100390442":3},{"organization":4,"armGroups":7,"interventions":43,"overallOfficials":58,"centralContacts":66,"locations":74,"responsibleParty":87,"collaborators":11,"id":89,"slug":90,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":91,"sex":97,"minAge":98,"maxAge":11,"enrollmentInfo":99,"targetDuration":11,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":76,"whyStopped":11,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8,16,19,22,25,28,31,34,37,40],{"label":9,"type":10,"description":11,"interventionNames":12},"Located\u002Fresected colorectal cancer","ACTIVE_COMPARATOR",null,[13,14,15],"Biological: Blood sampling","Procedure: Liver biopsy","Biological: Stool collect",{"label":17,"type":10,"description":11,"interventionNames":18},"Advanced colorectal cancer",[13,15],{"label":20,"type":10,"description":11,"interventionNames":21},"Located\u002Fresected pancreatic cancer",[13,14,15],{"label":23,"type":10,"description":11,"interventionNames":24},"Advanced pancreatic cancer",[13,15],{"label":26,"type":10,"description":11,"interventionNames":27},"Located\u002Fresected biliary tract cancer",[13,14,15],{"label":29,"type":10,"description":11,"interventionNames":30},"Advanced biliary tract cancer",[13,15],{"label":32,"type":10,"description":11,"interventionNames":33},"Located\u002Fresected gastroesophageal cancer",[13,14,15],{"label":35,"type":10,"description":11,"interventionNames":36},"Advanced gastroesophageal cancer",[13,15],{"label":38,"type":10,"description":11,"interventionNames":39},"Located\u002Fresected neuroendocrine cancer",[13,14,15],{"label":41,"type":10,"description":11,"interventionNames":42},"Advanced neuroendocrine cancer",[13,15],[44,49,54],{"type":45,"name":46,"description":47,"armGroupLabels":48,"otherNames":11},"BIOLOGICAL","Blood sampling","Blood collection (50 ml) will be performed for all patients at baseline, at 1 month post-operative for resected patients (+ at the end of neoadjuvant treatment \u002F before surgery if patient receives neoadjuvant treatment), and at 2-3 months after the beginning of the treatments in patients with metastases (+ at each progression).\n\nFollowing analysis should be performed with\n\n* serum for protein assays and characterization analysis of cytokines, new tumor markers and micro-RNA ...;\n* plasma for protein assays and characterization analysis of micro-RNA, VEC (the content of proteins, RNA, micro-RNA and DNA) and metabolomics;\n* PBMC for flow cytometry analysis, isolation macrophages;\n* whole blood for circulating tumor DNA (mutations by NGS, ddPCR,…; methylation) and circulating tumor cells.",[29,17,35,41,23,26,9,32,38,20],{"type":50,"name":51,"description":52,"armGroupLabels":53,"otherNames":11},"PROCEDURE","Liver biopsy","An intraoperative liver biopsy will be performed at free edge of liver with a triangular sample for local resected patients.\n\nThis biopsy will be done with scissors, then patients will receive intraoperative hemostasis with mono- or bipolar coagulation. This procedure will be under laparoscopy or laparotomy without extending standard processing time.\n\nThis biopsy seeks to allow the evaluate liver modifications testifying the preparing for premetastatic niche, which would allow to identify the patients with risk for hepatic relapsing; the same analysis on the tumors will be performed.",[26,9,32,38,20],{"type":45,"name":55,"description":56,"armGroupLabels":57,"otherNames":11},"Stool collect","Stool collection will be performed for all patients at baseline, at 1 month post-operative for resected patients (+ at the end of neoadjuvant treatment \u002F before surgery if patient receives neoadjuvant treatment), and at 2-3 months after the beginning of the treatments in patients with metastases (+ at each progression).\n\nAnalysis will be performed for microbiota and metabolism analysis.",[29,17,35,41,23,26,9,32,38,20],[59,63],{"name":60,"affiliation":61,"role":62},"Frédérique PESCHAUD, MD, PhD","Digestive Surgery Department, Ambroise Paré Hospital, APHP","PRINCIPAL_INVESTIGATOR",{"name":64,"affiliation":61,"role":65},"Cindy NEUZILLET, MD","STUDY_DIRECTOR",[67,71],{"name":60,"role":68,"phone":69,"phoneExt":11,"email":70},"CONTACT","+33 1 49 09 53 35","frederique.peschaud@aphp.fr",{"name":64,"role":68,"phone":72,"phoneExt":11,"email":73},"+33 1 47 11 15 15","cindy.neuzillet@gmail.com",[75],{"facility":61,"status":76,"city":77,"state":11,"zip":78,"country":79,"countryCode":80,"cosmosGeoPoint":81,"geoPoint":86,"contacts":11},"RECRUITING","Boulogne-Billancourt","92100","France","FR",{"type":82,"coordinates":83},"Point",[84,85],2.24128,48.83545,{"lat":85,"lon":84},{"type":88,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100390442","interaction-between-host-microenvironment-and-immunity-on-gastrointestinal-neoplasms-100390442",false,"NCT04363983","Interaction Between Host, Microenvironment and Immunity on Gastrointestinal Neoplasms","Interaction Between Host, Microenvironment and Immunity on Gastrointestinal Neoplasms: A Retro-prospective Cohort Study","HoMING","Inclusion Criteria:\n\n* Carcinoma of colorectal, pancreatic, biliary tract or gastro-oesophageal, or neuroendocrine digestive tumors with cytologically or histologically proven, regardless of the stage;\n* Diagnosis between 1998 and 2030;\n* Be \\>\u002F= 18 years;\n* Have obtained signed informed consent (exemption for dead patients);\n* Affiliated to the French social security - welfare system in France (CMU included).\n\nExclusion Criteria:\n\n* Patient under tutoraship or curatorship;\n* Foreign patient under AME schema, a medical help from the state in France;\n* Pregnant or breastfeeding women (for prospective study);\n* Any clinical, psychological or social reason which should influence patient compliance with protocol, according to investigator;\n* Patient refusal.","ALL","18 Years",{"count":100,"type":101},6300,"ESTIMATED","INTERVENTIONAL",[104],"NA","The primary objective: association study of characteristics of tumoral microenvironment and immunity of digestive cancers with patients' overall survival (OS).",[107],"Gastrointestinal Neoplasms",[109,110,111,112,113],"gastrointestinal cancer","micro-environment","immunity","host","microbiota","2022-02-09",{"date":116,"type":117},"2022-02-23","ACTUAL",{"date":119,"type":117},"2021-01-13",{"date":121,"type":101},"2031-01",{"name":5,"class":6},1]